Biogen (BIIB)
200.79
-2.37 (1.17%)
Upcoming Events
Latest Headlines
Biogen (BIIB) PT Raised to $280 at Guggenheim
July 21, 2026 6:45 AM - StreetInsider
Biogen (BIIB) PT Lowered to $215 at BofA Securities
July 21, 2026 5:31 AM - StreetInsider
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
July 16, 2026 7:47 AM - PR NewsWire
FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
July 15, 2026 1:29 PM - StreetInsider
Biogen names Michael J. Parini as chief legal officer
July 15, 2026 8:15 AM - StreetInsider
Biogen Appoints Michael J. Parini as Chief Legal Officer
July 15, 2026 8:15 AM - StreetInsider
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox
July 14, 2026 11:33 AM - StreetInsider
Real-world Leqembi study shows 82% of Alzheimer's patients stable
July 14, 2026 11:15 AM - StreetInsider
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Tre
July 14, 2026 11:15 AM - PR NewsWire
Biogen Phase 2 data shows diranersen slows Alzheimer's decline
July 14, 2026 9:15 AM - StreetInsider
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
July 14, 2026 9:15 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB)
July 14, 2026 7:56 AM - StreetInsider
FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
July 13, 2026 5:37 PM - StreetInsider
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 13, 2026 5:37 PM - PR NewsWire
Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
July 13, 2026 8:07 AM - StreetInsider
Stoke Therapeutics names Thomas McCauley as chief scientific officer
July 13, 2026 7:30 AM - StreetInsider
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
July 13, 2026 7:30 AM - BizWire
Leqembi subcutaneous data shows similar efficacy to IV in Alzheimer's
July 13, 2026 5:43 AM - StreetInsider
Truist Securities Upgrades Biogen (BIIB) to Buy
July 13, 2026 5:05 AM - StreetInsider
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�
July 12, 2026 11:15 AM - PR NewsWire
Biogen (BIIB) PT Lowered to $222 at Morgan Stanley
July 8, 2026 8:07 AM - StreetInsider
Biogen (BIIB) PT Raised to $242 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Biogen (BIIB) PT Raised to $157 at HSBC
July 6, 2026 1:34 AM - StreetInsider
Biogen expects $164M R&D charge to hit Q2 2026 earnings
July 1, 2026 4:09 PM - StreetInsider
Form 8-K BIOGEN INC. For: Jul 01
July 1, 2026 4:09 PM - SEC Filing
Stoke Therapeutics completes enrollment in Phase 3 Dravet study
June 30, 2026 8:01 AM - StreetInsider
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
June 30, 2026 8:00 AM - BizWire
Biogen (BIIB) PT Raised to $256 at Needham
June 29, 2026 8:17 AM - StreetInsider
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
June 29, 2026 8:00 AM - StreetInsider
Biogen to present Phase 2 Alzheimer's drug data at AAIC 2026
June 29, 2026 6:59 AM - StreetInsider
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
June 29, 2026 6:59 AM - StreetInsider
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
June 22, 2026 9:05 AM - StreetInsider
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026 8:30 AM - StreetInsider
Biogen (BIIB) Reiterated at Overweight by Cantor Fitzgerald: Advancing with BIIB080
June 22, 2026 7:33 AM - StreetInsider
Needham Reiterates Buy Rating on Biogen (BIIB)
June 18, 2026 7:06 AM - StreetInsider
Biogen to acquire RayThera for up to $1 billion
June 17, 2026 6:59 PM - StreetInsider
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
June 17, 2026 6:59 PM - Globe NewsWire
Biogen (BIIB) PT Lowered to $221 at Mizuho
June 15, 2026 6:38 AM - StreetInsider
Form 4 BIOGEN INC. For: Jun 09 Filed by: HAWKINS WILLIAM A
June 11, 2026 5:51 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: SHERWIN STEPHEN A
June 11, 2026 5:48 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Rowinsky Eric K
June 11, 2026 5:46 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Mantas Jesus B
June 11, 2026 5:45 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: LANGER SUSAN
June 11, 2026 5:35 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Patolawala Monish D
June 11, 2026 5:33 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Pangalos Menelas N
June 11, 2026 5:22 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Minor Lloyd
June 11, 2026 5:17 PM - SEC Filing
Form 4 BIOGEN INC. For: Jun 09 Filed by: Freire Maria C
June 11, 2026 5:09 PM - SEC Filing
Form 8-K BIOGEN INC. For: Jun 09
June 10, 2026 4:54 PM - SEC Filing
Form 8-K/A BIOGEN INC. For: May 14
June 10, 2026 4:50 PM - SEC Filing
Needham Upgrades Biogen (BIIB) to Buy
June 8, 2026 6:34 AM - StreetInsider
Form SCHEDULE 13G/A BIOGEN INC. Filed by: FMR LLC
June 5, 2026 10:13 AM - SEC Filing
Biogen's salanersen gets FDA breakthrough therapy designation for SMA
June 4, 2026 7:30 AM - StreetInsider
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
June 4, 2026 7:30 AM - StreetInsider
UCB and Biogen report positive results for lupus drug dapirolizumab pegol
June 4, 2026 5:54 AM - StreetInsider
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
June 4, 2026 1:00 AM - StreetInsider
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
May 28, 2026 4:01 PM - BizWire
Biogen (BIIB) PT Raised to $227 at RBC Capital
May 27, 2026 5:42 AM - StreetInsider
Biogen and Denali discontinue Parkinson's drug after trial fails
May 21, 2026 6:00 PM - StreetInsider
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 21, 2026 6:00 PM - StreetInsider
Biogen (BIIB) PT Raised to $225 at Piper Sandler
May 15, 2026 8:11 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Biogen (BIIB)
May 15, 2026 6:38 AM - StreetInsider
Evercore ISI Reinstates Biogen (BIIB) at Outperform
May 14, 2026 4:59 PM - StreetInsider
Biogen (BIIB) PT Raised to $300 at Oppenheimer
May 14, 2026 12:04 PM - StreetInsider
Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'
May 14, 2026 8:35 AM - StreetInsider
Form 8-K BIOGEN INC. For: May 14
May 14, 2026 8:31 AM - SEC Filing
Mizuho Reiterates Outperform Rating on Biogen (BIIB)
May 14, 2026 8:17 AM - StreetInsider
Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'
May 14, 2026 7:44 AM - StreetInsider
Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'
May 14, 2026 7:29 AM - StreetInsider
Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s
May 14, 2026 7:16 AM - StreetInsider
Biogen's diranersen shows tau reduction in Alzheimer's trial
May 14, 2026 6:59 AM - StreetInsider
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026 6:59 AM - Globe NewsWire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026 8:30 AM - Globe NewsWire
FDA extends review period for Eisai's LEQEMBI subcutaneous injection
May 8, 2026 2:30 AM - StreetInsider
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
May 8, 2026 2:30 AM - PR NewsWire
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
May 7, 2026 6:02 PM - PR NewsWire
Bright Horizons Family Solutions and Remitly Global to Join S&P SmallCap 600
May 7, 2026 5:18 PM - StreetInsider
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A BIOGEN INC. Filed by: FMR LLC
May 6, 2026 11:01 AM - SEC Filing
Form 4 BIOGEN INC. For: May 01 Filed by: Keeney Adam
May 5, 2026 4:12 PM - SEC Filing
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
May 5, 2026 6:37 AM - BizWire
Freedom Broker Upgrades Biogen (BIIB) to Buy, raises PT to $245
May 1, 2026 1:05 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
May 1, 2026 6:52 AM - StreetInsider
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
April 30, 2026 4:01 PM - BizWire
Biogen (BIIB) PT Raised to $190 at Truist Securities
April 30, 2026 4:00 PM - StreetInsider
Biogen (BIIB) PT Raised to $222 at RBC Capital
April 30, 2026 8:28 AM - StreetInsider
Biogen (BIIB) PT Raised to $196 at Wedbush
April 30, 2026 8:26 AM - StreetInsider
Biogen (BIIB) PT Raised to $206 at Morgan Stanley
April 30, 2026 7:57 AM - StreetInsider
Biogen (BIIB) PT Lowered to $200 at Bernstein SocGen Group
April 30, 2026 7:35 AM - StreetInsider
Biogen (BIIB) PT Raised to $260 at Guggenheim
April 30, 2026 6:41 AM - StreetInsider
Form SCHEDULE 13G BIOGEN INC. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 5:02 PM - SEC Filing
Biogen (BIIB) PT Raised to $203 at BofA Securities
April 29, 2026 2:58 PM - StreetInsider
Biogen shares rise after Q1 beat; full-year profit outlook slashed
April 29, 2026 6:55 AM - StreetInsider
Form 10-Q BIOGEN INC. For: Mar 31
April 29, 2026 6:41 AM - SEC Filing
Form 8-K BIOGEN INC. For: Apr 29
April 29, 2026 6:11 AM - SEC Filing
Biogen (BIIB) Tops Q1 EPS by 62c; cuts EPS guidance
April 29, 2026 6:05 AM - StreetInsider
Form ARS BIOGEN INC. For: Dec 31
April 28, 2026 4:47 PM - SEC Filing
Form DEFA14A BIOGEN INC.
April 28, 2026 4:43 PM - SEC Filing
Form DEF 14A BIOGEN INC. For: Jun 09
April 28, 2026 4:35 PM - SEC Filing
Truist Securities Reiterates Hold Rating on Biogen (BIIB)
April 27, 2026 9:45 AM - StreetInsider
U.S. Biotech stocks: Q1 earnings previews
April 26, 2026 8:00 PM - StreetInsider
Biogen (BIIB) PT Raised to $200 at BofA Securities
April 24, 2026 3:38 PM - StreetInsider
Biogen (BIIB) PT Raised to $185 at JPMorgan
April 23, 2026 8:27 AM - StreetInsider
Full Article List
